How prostate cancer becomes treatment resistant

Scientists have identified how prostate cancer transforms into a deadly treatment-resistant prostate cancer subtype called neuroendocrine prostate cancer (NEPC) following treatment with anti-androgen therapy. Their findings -- which include the metabolic rewiring and the epigenetic alteration that drives this switch -- reveal that an FDA-approved drug holds potential as a NEPC treatment.